James Quigley
Stock Analyst at Morgan Stanley
(0.54)
# 3,836
Out of 4,734 analysts
20
Total ratings
50%
Success rate
-25.02%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Equal-Weight | $45 → $49 | $40.61 | +20.66% | 5 | Nov 6, 2024 | |
| NVS Novartis AG | Downgrades: Neutral | $119 → $121 | $97.53 | +24.06% | 1 | Sep 5, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $7.27 | +44.43% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $23.76 | +68.35% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $4.11 | +289.29% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $45 → $49
Current: $40.61
Upside: +20.66%
Novartis AG
Sep 5, 2024
Downgrades: Neutral
Price Target: $119 → $121
Current: $97.53
Upside: +24.06%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $7.27
Upside: +44.43%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $23.76
Upside: +68.35%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $4.11
Upside: +289.29%